Modality
Gene Editing
MOA
MALT1i
Target
SGLT2
Pathway
Ferroptosis
RB
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Jun 2028
Phase 2Current
NCT05373988
1,876 pts·RB
2018-02→2028-06·Completed
1,876 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-282.2y awayPh2 Data· RB
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2028-06-28 · 2.2y away
RB
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05373988 | Phase 2 | RB | Completed | 1876 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |